Author | Mary L. Mckenney, NP

Articles

Tailoring Treatment for Multiple Myeloma Patients With Relapsed and Refractory Disease

March 16, 2010

Responses to treatment of relapsed and refractory multiple myeloma are characteristically short, and median survival is as brief as 6 months. Although prognostic factors in the context of relapsed and refractory disease require further characterization, high-risk patients include those with certain cytogenetic abnormalities, high β2-microglobulin, and low serum albumin.